The company will unveil the platform at the 49th Drug Information Association (DIA) annual meeting scheduled to be held between 23 June 2013 and 27 June 2013 in Boston.
ICD+ will help companies in enhancing their clinical development expertise by providing appropriate technology and optimized processes. It enables sponsors to make faster decisions and uniform approach to trials globally.
SynteractHCR CEO Wendel Barr said, "As we strive to streamline clinical trials and deliver better therapies in healthcare, we are confident that with ICD+, we offer a great solution to our clients."
"We collaborate with our clients to meet their project objectives, deliver timely results, and provide high quality work that exceeds their expectations, and ICD+ is the efficient approach we use to guide the process," added Barr.
SynteractHCR currently operates from 16 locations worldwide to support Phase I-IV trials.